Search results
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
Zacks· 1 day agoVir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 5 days agoMerus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 days ago...discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel...
Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead...
Benzinga· 4 days agoStrasbourg, France, June 3, 2024, 7:30 a.m. CET – Transgene TNG, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer today announces that the ...
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis...
Benzinga· 3 days agoIn heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 days agoRNAi Therapeutics and Technology Market Worth USD 5.36 Billion by 2031 at 16.6% CAGR- Exclusive Report by InsightAce Analytic Pvt. Ltd. PR Newswire JERSEY CITY, N.J., June 4, 2024 JERSEY CITY, N.J., June 4, 2024 /PRNewswire/ -- InsightAce Analytic
Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of...
KOIN News 6 Portland· 5 days agoKeymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 4 days agoUTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics
